News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
Bausch Health Companies Inc. and Salix Pharmaceuticals release Liver Health Trends Report highlighting need for improved chronic liver disease care, education, and management -
-
-
COMMUNIQUÉ DE PRESSE
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
Bausch Health, Canada, part of Bausch Health Companies, receives Health Canada approval for new acne treatment CABTREO, a triple-combination topical gel. Dermatology breakthrough for Canadians -
COMMUNIQUÉ DE PRESSE
Santé Canada approuve (Pr)CABTREO(MC) (phosphate de clindamycine, adapalène et peroxyde de benzoyle), un traitement topique à triple combinaison pour l'acné vulgaire chez les patients âgés de 12 ans et plus
Bausch Health Canada Inc. annonce l'approbation par Santé Canada de PrCABTREO, traitement topique à triple combinaison pour l'acné vulgaire. Disponible Q4 2024
